Mucous membrane pemphigoid with immunoglobulin G autoantibodies against full-length and 120-kDa ectodomain of BP180

Journal of Dermatology

Volumn 38, Issue 2, 2011, Pages 169-172

  Choi, Yuri ^a   Lee, Sang Eun ^a   Fukuda, Shunpei ^b   Hashimoto, Takashi ^b   Kim, Soo Chan ^a  

^a Yonsei University College of Medicine   (South Korea)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

bullous pemphigoid antigen 2; LAD 1; mucous membrane pemphigoid

Indexed keywords

ANTIGEN; AUTOANTIBODY; BULLOUS PEMPHIGOID ANTIGEN 2; DAPSONE; IMMUNOGLOBULIN G ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; UNCLASSIFIED DRUG;

AGED; ANTIGEN RECOGNITION; ARTICLE; CASE REPORT; CONJUNCTIVA; CONJUNCTIVITIS; CORNEA NEOVASCULARIZATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FACE; GINGIVITIS; HUMAN; IMMUNOBLOTTING; MALE; MOUTH MUCOSA; MUCOUS MEMBRANE PEMPHIGOID; PROTEIN DOMAIN; SCAR; SKIN ATROPHY; SYMBLEPHARON;

AGED; AUTOANTIBODIES; AUTOANTIGENS; HUMANS; IMMUNOGLOBULIN G; MALE; NON-FIBRILLAR COLLAGENS; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; PEMPHIGOID, BULLOUS;

EID: 79251567098     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2010.01072.x     Document Type: Article

References (11)

1. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138: 370-379.
2. Fleming TE, Korman NJ,. Cicatricial pemphigoid. J Am Acad Dermatol 2000; 43: 571-591; quiz 91-4.
3. Bruch-Gerharz D, Hertl M, Ruzicka T,. Mucous membrane pemphigoid: clinical aspects, immunopathological features and therapy. Eur J Dermatol 2007; 17: 191-200.
4. Oyama N, Setterfield JF, Powell AM, et al. Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity. Br J Dermatol 2006; 154: 90-98.
5. Van den Bergh F, Giudice GJ,. BP180 (type XVII collagen) and its role in cutaneous biology and disease. Adv Dermatol 2003; 19: 37-71.
6. Powell AM, Sakuma-Oyama Y, Oyama N, et al. Collagen XVII/BP180: a collagenous transmembrane protein and component of the dermoepidermal anchoring complex. Clin Exp Dermatol 2005; 30: 682-687.
7. Zone JJ, Taylor TB, Meyer LJ, et al. The 97 kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, BPAg2. J Invest Dermatol 1998; 110: 207-210.
8. McCluskey P, Chang JH, Singh R, et al. Methotrexate therapy for ocular cicatricial pemphigoid. Ophthalmology 2004; 111: 796-801.
9. Schmidt E, Skrobek C, Kromminga A, et al. Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol 2001; 145: 778-783.
10. Lee JB, Liu Y, Hashimoto T,. Cicatricial pemphigoid sera specifically react with the most C-terminal portion of BP180. J Dermatol Sci 2003; 32: 59-64.
11. Hirako Y, Nishizawa Y, Sitaru C, et al. The 97-kDa (LABD97) and 120-kDa (LAD-1) fragments of bullous pemphigoid antigen 180/type XVII collagen have different N-termini. J Invest Dermatol 2003; 121: 1554-1556.